Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-18-004805
Filing Date
2018-04-20
Accepted
2018-04-20 16:11:11
Documents
8
Period of Report
2018-05-16
Effectiveness Date
2018-04-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A mirati2018proxy.htm DEF 14A 530843
2 g368600a06.jpg GRAPHIC 14621
3 g368600a09.jpg GRAPHIC 3453
4 g641197a07.jpg GRAPHIC 8973
5 g775045a09.jpg GRAPHIC 11606
6 g775045a11.jpg GRAPHIC 11606
7 votingcardside1v2.jpg GRAPHIC 105708
8 votingcardside2.jpg GRAPHIC 71076
  Complete submission text file 0001628280-18-004805.txt   829115
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35921 | Film No.: 18766790
SIC: 2834 Pharmaceutical Preparations